ACT-300

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameACT-300
Drug Alias NameACT300ACT-300
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseDigestive System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesXiamen Amoytop Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXiamen Amoytop Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseDigestive System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A